Vaccines shine for CSL

In “difficult global environment” vaccines division managed 16% profit increase CSL’s newly-renamed vaccines division CSL Seqirus has been one of the brightest divisions for the Australian pharmaceutical giant, with both its revenue and profits into double digits. While posting an overall five per cent drop in profit to $USD 2.25 billion ($AUD 3.23 billion) for